Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanezumab versus placebo in amyotrophic lateral sclerosis
NL-OMON37243Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Ozanezumab with Placebo (2 arms). Primary endpoints: ALS Functional Rating Scale-Revised and Survival. Started Jan 2013; status: active, not recruiting.
02
Drugs
ozanezumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON37243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37243.